Fulgent Genetics, Inc.
NASDAQ:FLGTMedical - Diagnostics & Research
+$0.33 today
- Market cap
- $702.11M
- Beta
- 0.92
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$2.39
Volume 0.39M
Average 0.55M
FLGT Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
Fulgent Genetics, Inc.NASDAQ: FLGT
Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Investing cash flow dips below year-ago levels
Q1 FY2026 investing cash flow of $10.94M fell 60.6% year over year, behind the +471.0% change in trailing-twelve-month investing cash flow. Sequentially, it fell 1.9% from the prior quarter.
Context
- Investing cash flow amounted to 34.5% of revenue in FY2025, up 13.9 pp from a year earlier.
- Investing cash flow increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -60.6% toward the trailing-twelve-month pace of +471.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 111.37M USD
- Year-over-year change
- +290.9%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 111.37M | +290.9% |
| FY2024 | 2024-12-31 | (58.35M) | -250.0% |
| FY2023 | 2023-12-31 | 38.9M | +114.9% |
| FY2022 | 2022-12-31 | (261.31M) | +52.2% |
| FY2021 | 2021-12-31 | (546.55M) | — |
Investing Cash Flow vs competitors
How FLGT compares with its peers on the latest reported figures
- FLGT's LTM Mar 2026 investing cash flow of $94.58M is the 3rd largest of the 8 companies compared; the peer median is $38.64M.
- Its year-over-year change of +471.0% is the 2nd highest of 7, against a peer median of +3.5%.
- Investing cash flow amounts to 29.5% of revenue for FLGT, versus a peer median of 6.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $187.06M | +1913.6% | — | 6.9% | |
| LTM Sep 2026 | $117.66M | -140.8% | — | 9.2% | |
| LTM Mar 2026 | $94.58M | +471.0% | — | 29.5% | |
| LTM Mar 2026 | $46.04M | -28.0% | — | 71.4% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $38.64M | -28.5% | -24.2% | 8.5% |
| LTM Mar 2026 | $25.6M | +95.4% | -29.3% | 3.1% | |
| LTM Jun 2026 | $19.9M | +35.0% | — | 2.6% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $12.22M | — | — | 3.1% |
FRNMFreenome, Inc. Common stock | — | — | — | — | — |
| Peer median (excluding FLGT) | $38.64M | +3.5% | -26.8% | 6.9% | |
Competitors are the stored peer set for FLGT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 506.24M | 141.92M | (175.24M) | (43.82M) | (61.63M) |
| Depreciation & Amortization | 11M | 32.66M | 26.14M | 24.93M | 24.12M |
| Deferred Income Tax | (7.84M) | 831K | 7.61M | (5.15M) | (1.21M) |
| Stock-Based Compensation | 15.88M | 32.64M | 42.92M | 44.48M | 39.58M |
| Change in Working Capital | (2.68M) | 2.01M | 2.84M | (7.24M) | (117.63M) |
| Accounts Receivables | 42.3M | 68.64M | 2.39M | (16.3M) | (23.25M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (12.21M) | (25.34M) | (6.9M) | 3.07M | 550K |
| Other Working Capital | (32.77M) | (41.29M) | 7.35M | 6M | (94.93M) |
| Other Non-Cash Items | 15.97M | 43.46M | 122.73M | 7.86M | 15.14M |
| Operating Cash Flow | 538.58M | 253.52M | 27M | 21.06M | (101.64M) |
| Capital Expenditures | (23.84M) | (18.78M) | (22.21M) | (40.32M) | (22.57M) |
| Acquisitions (Net) | (61.87M) | (182.68M) | (399K) | 0 | 3.78M |
| Purchases of Investments | (730.49M) | (432.98M) | (491.91M) | (472.42M) | (80.84M) |
| Sales of Investments | 269.59M | 372.71M | 552.64M | 454.07M | 211.01M |
| Other Investing Activities | 31K | 412K | 775K | 313K | 5K |
| Investing Cash Flow | (546.55M) | (261.31M) | 38.9M | (58.35M) | 111.37M |
| Debt Repayment | (11K) | (1.07M) | (20M) | (1.77M) | (870K) |
| Common Stock Issued | 89.48M | 0 | 0 | 0 | 1K |
| Common Stock Repurchased | (4.16M) | (76.11M) | (27.79M) | (3.12M) | (13.92M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 96K | 31K | 3K | 51K | 0 |
| Financing Cash Flow | 85.41M | (77.14M) | (47.79M) | (4.85M) | (14.79M) |
| Effect of Forex Changes | 34K | (453K) | (149K) | (55K) | 105K |
| Net Change in Cash | 77.47M | (85.39M) | 17.97M | (42.19M) | (4.95M) |
| Free Cash Flow | 514.73M | 234.75M | 4.8M | (19.26M) | (124.21M) |
Fulgent Genetics, Inc.
NASDAQ:FLGT
Intrinsic Alpha fair value
Locked
Current Price
$25.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.